The Role of SGLT2 Inhibitors in Managing Heart Failure with Reduced Ejection Fraction

Faizul Maraam; Sarbaz Islam Khattak; Aazan hahib lodhi; Suleman Ahmad; Muhammad ibrahim; Sadaqat Ullah Rehmat; Sara Nisar

doi:10.62497/IRABCS.2024.38

Authors

Faizul Maraam KMU-Institute of Medical Sciences, Kohat. Author
Sarbaz Islam Khattak KMU-Institute of Medical Sciences, Kohat. Author
Aazan hahib lodhi KMU-Institute of Medical Sciences, Kohat. Author
Suleman Ahmad KMU-Institute of Medical Sciences, Kohat. Author
Muhammad ibrahim Bannu Medical College Author
Sadaqat Ullah Rehmat Ayub Medical College, Abbottabad. Author
Sara Nisar Women Medical and Dental College, Abbottabad. Author

DOI:

https://doi.org/10.62497/IRABCS.2024.38

Keywords:

heart failure, reduced ejection fraction, SGLT2 inhibitors, observational study

Abstract

Introduction: Heart failure with reduced ejection fraction (HFrEF) remains a significant clinical challenge despite advances in therapy. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as promising adjuncts in HFrEF management, with evidence from clinical trials suggesting improved outcomes. This study aims to evaluate the effectiveness and safety of SGLT2 inhibitors in HFrEF.

Methodology: A prospective, single-center observational study was conducted at Hayatabad Medical Complex, Peshawar, from June 2023 to March 2024. Forty-eight patients with HFrEF were enrolled, and baseline demographic, clinical, and laboratory data were collected. Patients received standard therapy alongside SGLT2 inhibitors. Follow-up assessments were performed over 10 months to evaluate changes in left ventricular ejection fraction (LVEF), symptoms, functional capacity, and adverse events.

Results: Following SGLT2 inhibitor therapy, a significant increase in LVEF (mean increase of 5.2 percentage points) was observed, accompanied by reductions in heart failure symptoms and improvements in functional capacity. Heart failure hospitalization rates decreased by 50%, with a favorable safety profile observed.

Conclusion: This study demonstrates the effectiveness and safety of SGLT2 inhibitors in managing HFrEF. The findings support their integration into clinical practice guidelines and emphasize the need for personalized, multidisciplinary approaches to optimize outcomes in HFrEF patients.

Downloads

Download data is not yet available.

References

Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, Packer M. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. The Lancet. 2020 Sep 19;396(10254):819-29.

Das US, Paul A, Banerjee S. SGLT2 inhibitors in heart failure with reduced ejection fraction. The Egyptian Heart Journal. 2021 Oct 24;73(1):93.

Starr JA, Pinner NA, Lisenby KM, Osmonson A. Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2021 Jun;41(6):526-36.

Silva-Cardoso J, Andrade A, Brito D, Ferreira J, Fonseca C, Peres M, Franco F, Moura B. SGLT-2 inhibitors: a step forward in the treatment of heart failure with reduced ejection fraction. Revista Portuguesa de Cardiologia (English Edition). 2021 Sep 1;40(9):687-93.

Heath R, Johnsen H, Strain WD, Evans M. Emerging horizons in heart failure with preserved ejection fraction: the role of SGLT2 inhibitors. Diabetes Therapy. 2022 Feb;13(2):241-50.

Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CS, Martinez F, Shah SJ. SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. The Lancet. 2022 Sep 3;400(10354):757-67.

Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Sattar N, Brueckmann M, Jamal W, Cotton D, Iwata T. Empagliflozin in patients with heart failure, reduced ejection fraction, and volume overload: EMPEROR-reduced trial. Journal of the American College of Cardiology. 2021 Mar 23;77(11):1381-92.

Verma S, Anker SD, Butler J, Bhatt DL. Early initiation of SGLT2 inhibitors is important, irrespective of ejection fraction: SOLOIST‐WHF in perspective. ESC Heart Failure. 2020 Dec;7(6):3261-7.

Muscoli S, Barillà F, Tajmir R, Meloni M, Della Morte D, Bellia A, Di Daniele N, Lauro D, Andreadi A. The new role of SGLT2 inhibitors in the management of heart failure: current evidence and future perspective. Pharmaceutics. 2022 Aug 18;14(8):1730.

Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Carson P, Anand I, Doehner W, Haass M, Komajda M. Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. Circulation. 2021 Jan 26;143(4):326-36.

Nassif ME, Windsor SL, Borlaug BA, Kitzman DW, Shah SJ, Tang F, Khariton Y, Malik AO, Khumri T, Umpierrez G, Lamba S. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nature medicine. 2021 Nov;27(11):1954-60.

McMurray JJ, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M. Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine. 2019 Nov 21;381(21):1995-2008.

Murphy SP, Ibrahim NE, Januzzi JL. Heart failure with reduced ejection fraction: a review. Jama. 2020 Aug 4;324(5):488-504.

Packer M. Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care. European Heart Journal. 2020 Jul 1;41(25):2393-6.

Tsampasian V, Baral R, Chattopadhyay R, Debski M, Joshi SS, Reinhold J, Dweck MR, Garg P, Vassiliou VS. The role of SGLT2 inhibitors in heart failure: a systematic review and meta-analysis. Cardiology research and practice. 2021 Aug 20;2021.

Tomasoni D, Fonarow GC, Adamo M, Anker SD, Butler J, Coats AJ, Filippatos G, Greene SJ, McDonagh TA, Ponikowski P, Rosano G. Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction. European journal of heart failure. 2022 Mar;24(3):431-41.

Omar M, Jensen J, Ali M, Frederiksen PH, Kistorp C, Videbæk L, Poulsen MK, Tuxen CD, Möller S, Gustafsson F, Køber L. Associations of empagliflozin with left ventricular volumes, mass, and function in patients with heart failure and reduced ejection fraction: a substudy of the empire HF randomized clinical trial. JAMA cardiology. 2021 Jul 1;6(7):836-40.

Requena-Ibanez JA, Santos-Gallego CG, Zafar MU, Badimon JJ. SGLT2-inhibitors on HFpEF patients. Role of ejection fraction. Cardiovascular Drugs and Therapy. 2023 Oct;37(5):989-96.

Mustapic I, Bakovic D, Susilovic Grabovac Z, Borovac JA. Impact of SGLT2 Inhibitor Therapy on Right Ventricular Function in Patients with Heart Failure and Reduced Ejection Fraction. Journal of clinical medicine. 2022 Dec 21;12(1):42.

Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, Garcia-Ropero A, Mancini D, Pinney S, Macaluso F, Sartori S, Roque M, Sabatel-Perez F, Rodriguez-Cordero A. Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. Journal of the American College of Cardiology. 2021 Jan 26;77(3):243-55.